Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Hepatitis C (HCV) is a disease that affects the liver. ITX 5061 is a new medication that is being tested to treat HCV. This study will evaluate the safety of ITX 5061 and examine different doses of the medication to evaluate which dose is the most effective at lowering the amount of HCV in the blood.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Criteria

Inclusion Criteria:

• Absence of HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit within 45 days prior to study entry

• Chronic HCV infection as defined and documented by testing. See protocol for details.

• HCV genotype 1 infection with source documentation from a College of American Pathologists (CAP) or Clinical Laboratory Improvement Amendments (CLIA) approved laboratory (or its equivalent) within 1 year prior to study entry. Those without a documented genotype result at screening will have a screening genotype performed either locally or provided by the study as described in the protocol.

• Serum or plasma HCV RNA greater than or equal to 100,000 IU/mL (5 log10) obtained within 45 days prior to study entry by any laboratory that has a CLIA certification or its equivalent

• Lack of significant hepatic fibrosis (bridging fibrosis or cirrhosis) confirmed by biopsy within 2 years of study entry or HCV FibroSURE score of less than or equal to METAVIR stage 2 within 1 year of study entry

• The following laboratory values obtained within 45 days prior to study entry:

1. White blood cell (WBC) count greater than or equal to 3000/mm3

2. Absolute neutrophil count (ANC) greater than or equal to 1000/mm3

3. Hemoglobin greater than or equal to 12 g/dL for men and greater than or equal to 11 g/dL for women

4. Platelet count greater than or equal to 120,000/mm3

5. Alanine aminotransferase (ALT) less than or equal to 5 x the upper limit of normal (ULN)

6. International normalized ratio (INR) less than 1.5

7. Total bilirubin less than or equal to ULN

8. Calculated creatinine clearance (CrCl) greater than or equal to 80 mL/min, as estimated by the Cockcroft-Gault equation. More information on this criterion can be found in the protocol.

• Hemoglobin A1c (HbA1c) less than or equal to 8.5% for participants with diabetes; must be obtained within 90 days prior to study entry

• Females of reproductive potential must have a negative serum or urine pregnancy test with a sensitivity of less than or equal to 25 mlU/mL within 45 days prior to study entry. More information on this criterion can be found in the protocol.

• All participants must agree not to participate in a conception process (e.g., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization)

• If participating in sexual activity that could lead to pregnancy, participants must agree to use two reliable methods of contraception simultaneously while receiving study treatment and for 6 weeks after stopping study treatment. More information on this criterion can be found in the protocol.

• Participants who are not of reproductive potential are eligible to participate without requiring the use of contraceptives, with acceptable documentation of either sterilization or menopause required. More information on this criterion can be found in the protocol.

• Able and willing to provide written informed consent

Exclusion Criteria:

• Prior receipt of any interferon or ribavirin (RBV)

• Prior receipt of any therapy for HCV, including experimental treatments

• Evidence of decompensated liver disease manifested by presence of or history of ascites, variceal bleeding, or hepatic encephalopathy

• History of Gilbert's syndrome

• Presence of other known causes of significant liver disease including chronic or acute hepatitis B, acute hepatitis A, hemochromatosis, or homozygote alpha-1 antitrypsin deficiency

• History of known hepatocellular carcinoma

• History of major organ transplantation with an existing functional graft

• History of uncontrolled seizure disorders

• Breastfeeding

• Use of prohibited medications within 14 days prior to study entry. More information on this criterion can be found in the protocol.

• Initiation or change in dose of any nonprohibited prescription medication within 14 days prior to study entry

• Known allergy/sensitivity or any hypersensitivity to components of study drug or its formulation

• Any condition including active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements

• Serious illness requiring systemic treatment and/or hospitalization within 24 weeks prior to study entry; serious illness including malignancy, active coronary artery disease within 24 weeks prior to study entry; other chronic medical conditions that may preclude completion of the study in the clinical research site (CRS) investigator's opinion. Such conditions may be discussed with the protocol chair/vice chair ([email protected]).

• Participation in a prior A5277 cohort